EUVIMEDEUVIMED entdecken
Crossref

Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma

Rashed N Herqash, Fai A Alkathiri, Ibrahim A Darwish

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04715-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Rashed N Herqash und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia. Hauptthemen laut MEDLINE: Nitriles, Lenalidomide, Drug Interactions, Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesLenalidomideDrug InteractionsPyrimidinesPyrazolesPrimary MyelofibrosisChromatography, High Pressure LiquidAnimalsRatsMaleAntineoplastic Combined Chemotherapy ProtocolsRats, Sprague-Dawley

Stichwörter der Autor:innen

Drug-drug interactionsLenalidomideMyelofibrosisPharmacokinetic studiesRuxolitinibTherapeutic drug monitoring

Substanzen

NitrilesLenalidomideruxolitinibPyrimidinesPyrazoles

Autor:innen und Institutionen

  • Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia. idarwish@ksu.edu.sa.

Zitieren

APA

Herqash, R. N., Alkathiri, F. A., & Darwish, I. A. (2024). Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04715-y

Vancouver

Herqash RN, Alkathiri FA, Darwish IA. Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04715-y

BibTeX
@article{Herqash2024,
  author = {Herqash, Rashed N and Alkathiri, Fai A and Darwish, Ibrahim A},
  title = {Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04715-y}
}
Kostenlos starten →